Ligand pharmaceuticals inc LGND.US 總覽分析
LGND 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上
LGND 近期報酬表現
-0.40%
Ligand pharmaceuticals inc
-0.65%
同產業平均
0.16%
S&P500
與 LGND 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
TEM | Tempus ai inc | - | 2 分 | 2 分 | 2 分 | 1 分 | |
VCYT | Veracyte inc | 4 分 | 5 分 | 2 分 | 5 分 | 1 分 | |
TXG | 10x genomics inc | 2 分 | 3 分 | 2 分 | 4 分 | 1 分 | |
CRL | Charles river laboratories international inc | 5 分 | 2 分 | 2 分 | 4 分 | 1 分 | |
ADPT | Adaptive biotechnologies corp | 4 分 | 5 分 | 2 分 | 2 分 | 1 分 |
- TEM Tempus ai inc價值 -趨勢 2 分波段 2 分籌碼 2 分股利 1 分查看更多
LGND 公司資訊
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.